The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The optimal frequency and timing of NGS testing in MPNs
Akriti Jain, MD, Cleveland Clinic, Cleveland, Ohio, discusses the optimal frequency and timing of mutational profiling with next-generation sequencing (NGS) in patients with myeloproliferative neoplasms (MPNs), suggesting it should be performed more frequently to monitor clonal dynamics and guide treatment decisions. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
